Interferon alpha-2b - Hanmi Pharmaceutical

Drug Profile

Interferon alpha-2b - Hanmi Pharmaceutical

Alternative Names: HM 10660A; LAPS-10660A; LAPS-IFNa

Latest Information Update: 18 Feb 2016

Price : $50

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cancer; Hepatitis C

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 31 Jul 2013 Phase-I/II clinical trials in Hepatitis C in Mexico (SC)
  • 03 May 2013 Phase-II clinical trials in Cancer in Netherlands (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top